Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Disease Awareness Ad Policy Is Unfair To Small Firms, BIO Says

Executive Summary

Restrictions on disease awareness advertisements proposed by FDA will hurt small biotech firms, the Biotechnology Industry Organization said

You may also be interested in...



Disease Awareness Ads Increase, Along With Firms’ Need For Clarity From FDA

Industry would like greater clarification from FDA on appropriate disease awareness advertising when the agency finalizes its draft guidance

Disease Awareness Ads Increase, Along With Firms’ Need For Clarity From FDA

Industry would like greater clarification from FDA on appropriate disease awareness advertising when the agency finalizes its draft guidance

Ads Linking “Help-Seeking” and Full Product Spots Helps Consumers – Pfizer

Similarities between branded ads and disease awareness ads may benefit consumers and should not be prohibited by FDA, Pfizer says

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS044109

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel